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Elevated 5hmC levels characterize DNA of the cerebellum in
Parkinson’s disease
Reinhard Stöger1, Paula J. Scaife2, Freya Shephard2 and Lisa Chakrabarti2
5-methylcytosine and the oxidation product 5-hydroxymethylcytosine are two prominent epigenetic variants of the cytosine base
in nuclear DNA of mammalian brains. We measured levels of 5-methylcytosine and 5-hydroxymethylcytosine by enzyme-linked
immunosorbent assay in DNA from post-mortem cerebella of individuals with Parkinson’s disease and age-matched controls.
5-methylcytosine levels showed no signiﬁcant differences between Parkinson’s disease and control DNA sample sets. In contrast,
median 5-hydroxymethylcytosine levels were almost twice as high (p < 0.001) in both male and female Parkinson’s disease
individuals compared with controls. The distinct epigenetic proﬁle identiﬁed in cerebellar DNA of Parkinson’s disease patients raises
the question whether elevated 5-hydroxymethylcytosine levels are a driver or a consequence of Parkinson’s disease.
npj Parkinsons Disease  (2017) 3:6 ; doi:10.1038/s41531-017-0007-3
INTRODUCTION
Parkinson’s disease (PD) is a progressive neurodegenerative
disorder with primary impairment of motor control. Functional
changes in the cerebellum, a brain structure operative in motor
learning and modulation of motor commands, are implicated in
the pathophysiology and clinical symptoms of PD.1 Within the
cerebellum reside two distinctive neuronal cell types, Purkinje cells
and granule cells, respectively, along with specialized glial cells, all
of which have 5-hydroxymethylcytosine (5hmC) enriched
throughout the bodies of expressed genes.2 Possible imbalances
of 5-methylcytosine (5mC) and 5hmC in cerebellar nuclear DNA of
PD individuals have not been investigated before.
RESULTS AND DISCUSSION
Our results demonstrate extensive inter-individual 5mC variation in
PD samples (Fig. 1a, c). The broad range of 5mC levels, however, is
also manifest in control individuals and does not differ between
the two cohorts. Age was considered as a factor contributing to the
variability of 5mC levels among individuals. Indeed, PD patients
were reported earlier to have an accelerated epigenetic age, a
ﬁnding that is based on measurements of methylation levels at 353
individual CpG sites in blood DNA.3 Quantiﬁcation of methylation
levels at individual CpG sites was not possible with our enzyme-
linked immunosorbent assay (ELISA) approach. However, based on
our genome-wide methylation measurements—representing the
sum total of all cytosine methylation events in cerebellar DNAs—
we detected no apparent correlation between 5mC levels and age
(Supplementary Fig. 1). This ﬁnding is consistent with two previous
studies reporting considerable 5mC variation in the cerebellum
among individuals who are not affected by Parkinson’s.4,5 In
comparison, 5hmC levels fall within a narrow range in the PD
group, which differs signiﬁcantly (p < 0.001) from the narrow range
detected in the control group (Fig. 1b). With the exception of two
outliers in the control group, cerebellar DNA samples of PD
individuals were found to have higher 5hmC levels (Fig. 1c). The
increase in levels of this epigenetic mark is sex-independent and
evident in both PD males and PD females (Fig. 1b). Age-related
increases in 5hmC levels occur in the mouse cerebellum during the
ﬁrst 12 months of life,6,7 a time span representing birth to middle
age in humans. The dynamics of cerebellar 5hmC levels in later
stages of life are not known to date. We analysed cerebellar DNA
samples from PD and control individuals whose age ranged
between 58 years and 93 years at time of death. Our data suggest
that genome-wide 5hmC levels do not change in the cerebellum as
a result of age during this period of life (Supplementary Fig. 1).
Elevated 5hmC levels in PD DNA samples reﬂect, in part at least,
epigenomic changes of granule cells, as these neurons outnumber
any other cell type of the cerebellum. It is not clear if the rise of
5hmC is a consequence of an altered physiology of the cerebellum
in PD individuals. Compensatory and pathological effects have
been proposed to explain the functional changes observed in the
cerebellum during the progression of Parkinson’s.1 Increased
5hmC levels have been reported before in human post-mortem
cerebellum of individuals with autism,8 a population group
showing high rates of parkinsonism in adulthood.9 Our ﬁndings
motivate an array-based approach to determine the epigenetic
age3 and, in combination with oxidative bisulﬁte sequencing, the
identiﬁcation of genomic regions and genes that show an altered
abundance of 5hmC in the cerebellum.5,10 Maps and measure-
ments of 5hmC in different anatomical brain regions will reveal
possible common molecular pathology shared by conditions
manifesting as parkinsonism.
MATERIALS AND METHODS
Cerebellum samples
Human brain sections and frozen brain samples were obtained
from the Human Tissue Authority-approved, Nottingham Health
Science Biobank (Nottingham University Hospitals NHS Trust), and
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Parkinson’s UK Brain Bank (Imperial College London). The tissue
banks granted us use of the tissue as end users. The Parkinson’s
tissue bank has approval from the Research Ethics Committee for
Wales ref 08/MRE09/31+5. The tissue collection and procedures at
the Nottingham University Hospitals Biobank have been ethically
approved by the Greater Manchester National Research Ethics
Service. This study was granted speciﬁc ethics approval by both of
the ethics committees serving the biobanks and also by the local
ethics committee at the School of Veterinary Medicine and
Science at the University of Nottingham.
Age at death for PD individuals ranged between 63–87 years
(females) and 58–83 years (males); for non-PD (control) individuals
age at death ranged between 61–93 years (females) and 58–90
years (males). For each PD sample used in this study, the Biobanks
provided us with age-matched control samples, which differed +/−5
years of age, or less. We performed analysis of covariance to explore
whether covariates such as post mortem interval or a different tissue
collection centre could have inﬂuenced our results. We detected no
effects of confounding variables (Supplementary Table 1).
Nuclear DNA extraction
Nuclear DNA pellets were isolated from human cerebellar tissue as
previously described11 and resuspended in 500 μl TE buffer (pH 7.5).
Samples were re-pelleted (13,000×g for 5min) before being
resuspended in 375 µl TE buffer with 20 µl lysis buffer (20% w/v
SDS in 50mM Tris, 20mM EDTA pH 7.8) and 3 µl Proteinase K (20
mg/ml) and were incubated at 37 °C for 1 h. In order to precipitate
protein cell wall debris, 200 µl saturated NaCl (>6.0M) was added,
mixed thoroughly by inversion and centrifuged at 12,500×g for 10
min. The supernatant was transferred to a fresh tube and an equal
volume of Tris-equilibrated phenol:chloroform:isoamyl alcohol
(25:24:1, Sigma Aldrich, Poole, UK) was added. This was brieﬂy
agitated and centrifuged at 13,000×g for 3min. The upper aqueous
phase was transferred to a fresh tube. DNA was precipitated by
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Fig. 1 Quantitation of 5mC and 5hmC in DNA of the cerebellum from age-matched control (n= 27; 11 females, 16 males) and PD individuals
(n= 36; 12 females (F), 24 males (M)). Data are presented as box-and-whisker plots and indicate the full range, interquartile range, and median
value in each group. Error bars represent SEM (a, b). The scatter plot depicts 5hmC and 5mC levels for individuals of the control and PD group
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adding 30 µl 1M Na acetate (pH 5.2) and two volumes pre-chilled
absolute ethanol and incubating at 4 °C for 2 h. Precipitated DNA
was centrifuged at 13,000×g for 20min. DNA was then washed
with cold 70% ethanol, thoroughly air-dried and resuspended in
TE buffer containing 20 µg/ml RNaseA. A Qubit dsDNA BR assay
(Life Technologies DNA, Warrington, UK) was used to quantify DNA.
DNA quality was determined using a Nanodrop 8000 spectro-
photometer (Thermo Fisher Scientiﬁc, Loughborough, UK).
Quantiﬁcation of global DNA methylation and
hydroxymethylation
Cerebellar genomic 5mC and 5hmC levels of PD and controls were
determined by colorimetric ELISA using the 5mC DNA ELISA kit
and Quest 5hmC DNA ELISA kit, respectively (Zymo Research,
Irvine, CA, USA). PD and control DNAs were analysed simulta-
neously and different batches of ELISA kits were used to analyse
all DNA samples, thereby limiting variation in measurements
resulting from potential procedural or batch discrepancies. Assays
were performed according to the manufacturer’s instructions
loading 100 ng of DNA per well. Absorbance at 405 nm was
captured using a LT4000 microplate reader (LabTech International,
East Sussex, UK). The percentage of global 5mC and 5hmC is
expressed as mean ± standard error mean (SEM).
Statistical analysis
All analyses were performed using IBM SPPS Statistics version 22
(IBM, Leeds, UK). The Kolmogorov–Smirnov test was used to assess
the distribution of data. Depending on distribution of data,
between-group comparisons were made using either one-way
analysis of variance or the Kruskal–Wallis test as appropriate, and if
signiﬁcant were followed by a Bonferroni post hoc test or
Mann–Whitney U test, respectively. Values of p≤ 0.05 are
considered signiﬁcant. Unless otherwise stated all data are
expressed as mean (standard error of mean).
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